{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:47:31Z","timestamp":1791474451579,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022537","name":"Canadian Society of Endocrinology and Metabolism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013333","name":"Hypertension Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijcha.2021.100725","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T13:53:33Z","timestamp":1612965213000},"page":"100725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-4613","authenticated-orcid":false,"given":"Jamie L.","family":"Benham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-717X","authenticated-orcid":false,"given":"Ronald J.","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella S.","family":"Daskalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7536-8497","authenticated-orcid":false,"given":"Alexander A.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-3843","authenticated-orcid":false,"given":"Doreen M.","family":"Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijcha.2021.100725_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ijcha.2021.100725_b0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ijcha.2021.100725_b0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcha.2021.100725_b0025","doi-asserted-by":"crossref","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41(12):2669-701. doi: 10.2337\/dci18-0033 [published Online First: 2018\/10\/07]","DOI":"10.2337\/dci18-0033"},{"key":"10.1016\/j.ijcha.2021.100725_b0030","doi-asserted-by":"crossref","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2018;42(Suppl 1):S1-S325.","DOI":"10.1016\/S1499-2671(17)31026-2"},{"issue":"10166","key":"10.1016\/j.ijcha.2021.100725_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijcha.2021.100725_b0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.ijcha.2021.100725_b0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"10166","key":"10.1016\/j.ijcha.2021.100725_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(18)32824-1","article-title":"Pump, pipes, and filter: do SGLT2 inhibitors cover it all?","volume":"393","author":"Verma","year":"2019","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.ijcha.2021.100725_b0055","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ijcha.2021.100725_b0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ijcha.2021.100725_b0065","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijcha.2021.100725_b0075","unstructured":"Higgins J, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. Available from http:\/\/handbook.cochrane.org\/. 2011."},{"issue":"4","key":"10.1016\/j.ijcha.2021.100725_b0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol Bull"},{"key":"10.1016\/j.ijcha.2021.100725_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijcha.2021.100725_b0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.amjcard.2009.02.048","article-title":"Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction","volume":"104","author":"Chen","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020498","article-title":"Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects","volume":"8","author":"Mahmoud","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcha.2021.100725_b0100","unstructured":"Altman DS, GD & Egger, M. Systematic reviews in health care : meta analysis in context (2nd ed). London: BMJ 2001."},{"issue":"7414","key":"10.1016\/j.ijcha.2021.100725_b0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ijcha.2021.100725_b0110","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"issue":"7109","key":"10.1016\/j.ijcha.2021.100725_b0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a\/3b CKD","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.ijcha.2021.100725_b0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"101190723","key":"10.1016\/j.ijcha.2021.100725_b0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ijcha.2021.100725_b0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0145","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0150","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"10.1016\/j.ijcha.2021.100725_b0155","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ijcha.2021.100725_b0160","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ijcha.2021.100725_b0165","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ijcha.2021.100725_b0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ijcha.2021.100725_b0175","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dom.13631","article-title":"Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial","volume":"21","author":"Gallo","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ijcha.2021.100725_b0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","article-title":"Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes","volume":"110","author":"Haering","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ijcha.2021.100725_b0185","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/dom.13681","article-title":"Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia","volume":"21","author":"Ji","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ijcha.2021.100725_b0190","doi-asserted-by":"crossref","unstructured":"Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2014;36(1):84-100 e9. doi: 10.1016\/j.clinthera.2013.11.002 [published Online First: 2014\/01\/01]","DOI":"10.1016\/j.clinthera.2013.11.002"},{"issue":"101147637","key":"10.1016\/j.ijcha.2021.100725_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ijcha.2021.100725_b0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13340-014-0184-9","article-title":"Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study","volume":"6","author":"Kashiwagi","year":"2014","journal-title":"Diabetology International"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/dom.12331","article-title":"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ijcha.2021.100725_b0210","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcha.2021.100725_b0215","doi-asserted-by":"crossref","unstructured":"Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clin Ther 2015;37(8):1773-88 e1. doi: 10.1016\/j.clinthera.2015.05.511 [published Online First: 2015\/07\/04]","DOI":"10.1016\/j.clinthera.2015.05.511"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0220","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.ijcha.2021.100725_b0225","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","article-title":"Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes","volume":"38","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ijcha.2021.100725_b0230","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.12543","article-title":"Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes","volume":"17","author":"Matthaei","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ijcha.2021.100725_b0235","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/dme.12814","article-title":"Empagliflozin as add-on to metformin in people with Type 2 diabetes","volume":"32","author":"Merker","year":"2015","journal-title":"Diabet Med"},{"issue":"8","key":"10.1016\/j.ijcha.2021.100725_b0240","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0250","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0255","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0260","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.ijcha.2021.100725_b0265","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ijcha.2021.100725_b0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13300-014-0072-0","article-title":"Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial","volume":"5","author":"Strojek","year":"2014","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.ijcha.2021.100725_b0275","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ijcha.2021.100725_b0280","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.ijcha.2021.100725_b0285","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ijcha.2021.100725_b0290","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diabetes"},{"issue":"7","key":"10.1016\/j.ijcha.2021.100725_b0295","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1753-0407.12634","article-title":"Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial","volume":"10","author":"Yang","year":"2018","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.ijcha.2021.100725_b0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.ijcha.2021.100725_b0305","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.ijcha.2021.100725_b0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ijcha.2021.100725_b0315","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","article-title":"A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.ijcha.2021.100725_b0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","article-title":"Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes","volume":"18","author":"Kawasoe","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.ijcha.2021.100725_b0325","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"issue":"18","key":"10.1016\/j.ijcha.2021.100725_b0330","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcha.2021.100725_b0335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"issue":"3","key":"10.1016\/j.ijcha.2021.100725_b0340","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906721000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906721000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:10:42Z","timestamp":1762492242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906721000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":68,"alternative-id":["S2352906721000130"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2021.100725","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2021.100725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100725"}}